2024
Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States
Ramdhanny A, Vaughn J, Epperla N. Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States. Blood 2024, 144: 3745. DOI: 10.1182/blood-2024-211747.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T cell therapyT-cell therapyChimeric antigen receptorChimeric antigen receptor T-cell therapyPresence of B symptomsLarge B-cell lymphomaB-cell lymphomaOverall survivalFood and Drug AdministrationRelative survivalB symptomsApproval of CAR-T cell therapyAdvent of chimeric antigen receptorCentral nervous system lymphomaMultivariable flexible parametric survival modelNervous system lymphomaMedian Follow-UpUS Food and Drug AdministrationPopulation-based cohort studySurveillance, EpidemiologyPeriod of diagnosisUS populationPersons per yearP-value <
2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Alderuccio J, Arcaini L, Watkins M, Beaven A, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert A, Olszewski A, Kim S, Hess B, Gaballa S, Ayyappan S, Castillo J, Argnani L, Voorhees T, Saba R, Chowdhury S, Vargas F, Reis I, Kwon D, Alexander J, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link B, Logothetis C, Herrera A, Friedberg J, Kahl B, Luminari S, Zinzani P, Lossos I. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances 2022, 6: 2035-2044. PMID: 35196377, PMCID: PMC9006265, DOI: 10.1182/bloodadvances.2021006844.Peer-Reviewed Original ResearchConceptsProgression-free survivalEastern Cooperative Oncology GroupMALT-IPIRituximab maintenanceOverall survivalHerpes zosterAssociated with longer progression-free survivalPerformance status 0 to 1Associated with shorter progression-free survivalHeterogeneous non-Hodgkin lymphomasPresence of B symptomsLonger progression-free survivalShorter progression-free survivalExtranodal marginal zone lymphomaOccurrence of herpes zosterMarginal zone lymphomaInternational Prognosis IndexNon-Hodgkin's lymphomaAdvanced-stage diseaseCooperative Oncology GroupStandard-of-careAdverse prognosis factorsAssociated with occurrenceImpact OSUpfront regimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply